Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Bioline RX Ltd Sponsored ADR ( (BLRX) ) is now available.
On March 23, 2026, BioLineRx reported audited 2025 results and said it remains on track to launch a Phase 1/2a first-in-human trial of GLIX1 in glioblastoma by the end of March, with three leading U.S. cancer centers participating. The study will first establish dosing and safety in up to 30 patients, with initial Phase 1 data expected in the first half of 2027, and will later expand into additional cohorts and cancer types, supported by ongoing pre-clinical work and a newly allowed U.S. patent that covers GLIX1 in an estimated 90% of cancers and extends protection to 2040.
The company highlighted continued momentum for motixafortide, including faster enrollment in the CheMo4METPANC Phase 2b pancreatic cancer trial and ongoing sickle cell gene therapy studies, while 2025 results reflected a shift to a leaner, royalty- and R&D-focused model, with $20.9 million in cash and no sales and marketing expenses after U.S. commercial operations were shut down in late 2024. Revenues fell to $1.2 million in 2025, mainly from APHEXDA royalties, but research and administrative costs declined sharply following the out-licensing of U.S. rights to motixafortide and restructuring, leaving the company guiding for a cash runway into the first half of 2027.
The most recent analyst rating on (BLRX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Bioline RX Ltd Sponsored ADR stock, see the BLRX Stock Forecast page.
Spark’s Take on BLRX Stock
According to Spark, TipRanks’ AI Analyst, BLRX is a Neutral.
BioLine RX Ltd’s overall stock score reflects significant revenue growth and strategic initiatives, but is weighed down by ongoing profitability challenges and a bearish technical outlook. The company’s strong cash position and potential in innovative treatments are promising, yet current revenue generation and market penetration remain hurdles.
To see Spark’s full report on BLRX stock, click here.
More about Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a development-stage biopharmaceutical company focused on oncology and rare diseases, with its shares traded on NASDAQ and TASE under the ticker BLRX. The company’s pipeline centers on GLIX1, a novel DNA damage response-targeting agent for glioblastoma and other cancers, and motixafortide, used in oncology and stem cell mobilization, while it also earns royalties from the U.S. commercialization of APHEXDA for stem cell mobilization.
Average Trading Volume: 14,863
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.76M
For an in-depth examination of BLRX stock, go to TipRanks’ Overview page.